If a patient’s 5‑fluorouracil (5‑FU) infusion pump is disconnected overnight, can the remaining medication be administered as a bolus?

No, the Remaining 5-FU Cannot Be Administered as a Bolus

If a 5-FU continuous infusion pump disconnects overnight, the remaining medication should NOT be given as a bolus—the missed dose should be omitted entirely, and the treatment cycle should proceed as scheduled. Attempting to "catch up" by administering the remaining infusion volume as a bolus fundamentally changes the pharmacokinetics and significantly increases toxicity risk without clear efficacy benefit.

Why Bolus Administration Is Contraindicated

Pharmacokinetic and Toxicity Concerns

The mode of 5-FU administration critically determines both efficacy and toxicity profiles. 1, 2

• Continuous infusion (46-48 hours) produces lower peak plasma concentrations but sustained drug exposure, which is the intended therapeutic approach in regimens like mFOLFOX6 and FOLFIRI 3, 4, 3
• Bolus administration creates dramatically higher peak concentrations, leading to substantially increased myelosuppression risk 2
• Recent PBPK modeling demonstrates that continuous infusion has lower myelotoxicity risk despite much higher total doses compared to bolus administration, specifically because it avoids toxic peak bone marrow concentrations 2

Evidence on Administration Mode

Multiple studies confirm that the method of 5-FU delivery is not interchangeable:

• Meta-analysis of 1,219 patients showed continuous infusion produces significantly less grade 3-4 hematologic toxicity (4%) compared to bolus administration (31%), P < 10^-16 1
• Even shortening a bolus injection from 2-4 minutes to 10-20 minutes significantly reduced response rates (27% vs 13%, P=0.02), demonstrating that administration timing directly impacts outcomes 5
• Standard regimens explicitly specify both bolus AND infusion components separately (e.g., 400 mg/m² bolus followed by 1200 mg/m²/day × 2 days continuous infusion) 3, 4

Recommended Management Approach

Immediate Actions

When a pump disconnection is discovered:

1. Document the time of disconnection and total infusion time completed 3
2. Do NOT attempt to administer remaining medication as bolus 1, 2
3. Assess patient for any signs of line complications (infection, thrombosis)

Treatment Continuation

The safest approach is to:

• Omit the missed portion of the continuous infusion entirely 3
• Proceed with the next scheduled treatment cycle as planned 3, 4
• Consider dose modifications for subsequent cycles only if clinically indicated based on toxicity assessment, not to "make up" for the missed dose 6

Important Safety Considerations

Guidelines specifically warn against medication errors with continuous infusions:

• NCCN explicitly recommends "limiting chemotherapy orders to 24-hour units (i.e., 1200 mg/m²/day NOT 2400 mg/m² over 46 hours) to minimize medication errors" 3, 7
• This recommendation exists precisely to prevent scenarios where providers might inadvertently give accumulated doses inappropriately 3

Common Pitfalls to Avoid

Do Not Attempt Dose Compensation

Never try to "catch up" on missed continuous infusion by:

• Administering remaining volume as rapid bolus (dramatically increases toxicity) 1, 2
• Extending the infusion beyond the protocol-specified timeframe (alters pharmacokinetics) 8
• Doubling the next cycle dose (increases toxicity without proven benefit) 6

Stability Concerns

If considering any deviation from standard administration:

• 5-FU solutions develop increasing concentrations of cardiotoxic metabolites (fluoroacetaldehyde and fluoromalonic acid semialdehyde) over time in pumps 8
• After 2-3 days at body temperature, fluoroacetaldehyde levels increase by factor of 2, and by factor >3 after 10 days 8
• Treatment periods should not exceed 3 days when using portable infusion pumps 8

Patient-Specific Factors

Consider that some patients may be at higher risk:

• Patients with DPD enzyme deficiency can develop life-threatening toxicity even with standard dosing 6, 9
• Prior severe fluoropyrimidine toxicity is a contraindication to dose escalation 6
• Cardiotoxicity from 5-FU is unpredictable and can occur with any administration method, though continuous infusion may have different risk profile than bolus 10, 11

Documentation and Follow-up

Ensure proper documentation includes:

• Exact time pump was connected and disconnected 12
• Estimated volume/dose actually delivered
• Patient assessment for any acute complications
• Plan for next treatment cycle without dose modification 3, 4